Familial adenomatous polyposis-associated desmoid disease: comprehensive review
BJS Open · 2026
DOI: 10.1093/bjsopen/zrag089 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BJS Open, 2026. Verfasst von Benjamin Zare und 4 weiteren Autor:innen. Beteiligte Einrichtung: St Mark's Centre for Familial Intestinal Cancer, St Mark's Hospital, London, UK. Hauptthemen laut MEDLINE: Adenomatous Polyposis Coli, Desmoid Tumors. Die Arbeit nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Familial adenomatous polyposis (FAP)-associated desmoid disease is a rare but important manifestation of FAP and remains a major cause of morbidity and mortality. In contrast to sporadic desmoids, which most commonly occur in the abdominal wall or extra-abdominal sites, approximately 70% of FAP-associated desmoids arise intra-abdominally, usually within the small bowel mesentery. These lesions can cause bowel and ureteric obstruction, sepsis, intestinal failure, and death. This review summarizes current evidence regarding the pathogenesis, risk factors, diagnosis, surveillance, and management of FAP-associated desmoid disease, and identifies key evidence gaps.
Methods
A literature search was performed in accordance with PRISMA methodology using Medline, Embase, PROSPERO, Cochrane, Campbell, and Joanna Briggs Institute databases. Original research studies, reviews, and guidelines relating to desmoid disease, FAP-associated desmoid disease, and FAP published up to August 2025 were eligible. Data were extracted and synthesized narratively by topic.
Results
Aberrant Wnt/β-catenin signalling resulting from a germline APC pathogenic variant and a somatic second hit underpin the development of FAP-associated desmoid disease. Established risk factors include a distal APC pathogenic variant, positive family history, and previous abdominal surgery. Diagnosis in patients with established FAP is usually clinicoradiological, and routine biopsy is generally unnecessary, except in select circumstances. Active surveillance is now recommended as first-line management for most patients because many lesions remain stable or regress spontaneously. Surgery is primarily reserved for complications, particularly in small bowel mesenteric disease, owing to substantial operative morbidity and a lack of demonstrated survival benefit from complete resection. Systemic therapy is indicated for progressive or symptomatic disease. Tyrosine kinase inhibitors and the γ-secretase inhibitor nirogacestat have demonstrated efficacy in randomized trials, although patients with FAP-associated disease comprise only a small proportion of enrolled patients. Evidence supporting the use of non-steroidal anti-inflammatory drugs and anti-oestrogens remains limited.
Conclusion
Important evidence gaps remain regarding optimal imaging strategies, predictors of aggressive disease, clinically meaningful trial endpoints, and FAP-specific treatment algorithms. Dedicated studies in genetically defined FAP cohorts are required to improve risk stratification and management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- St Mark's Centre for Familial Intestinal Cancer, St Mark's Hospital, London, UK.
- Department of Surgery and Cancer, Imperial College London, London, UK.
- Sarcoma Unit, University College London Hospitals NHS Foundation Trust, London, UK.
- Department of Medical Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy.
- Department of Colon and Rectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
- The Sanford R. Weiss, MD Center for Hereditary Colorectal Neoplasia, Department of Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio, USA.
ORCID-Profile: Benjamin Zare, David Liska
Zitieren
APA
Zare, B., Clark, S., Dileo, P., Liska, D., & Latchford, A. (2026). Familial adenomatous polyposis-associated desmoid disease: comprehensive review. BJS Open. https://doi.org/10.1093/bjsopen/zrag089
Vancouver
Zare B, Clark S, Dileo P, Liska D, Latchford A. Familial adenomatous polyposis-associated desmoid disease: comprehensive review. BJS Open. 2026. doi:10.1093/bjsopen/zrag089
BibTeX
@article{Zare2026,
author = {Zare, Benjamin and Clark, Susan and Dileo, Palma and Liska, David and Latchford, Andrew},
title = {Familial adenomatous polyposis-associated desmoid disease: comprehensive review},
journal = {BJS Open},
year = {2026},
doi = {10.1093/bjsopen/zrag089}
}
EUVIMED